Article de revue
Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia Ankara–vectored ebola Vaccines
In this phase 1 study of healthy volunteers, immunization with Ad26.ZEBOV or MVA-BN-Filo did not result in any vaccine-related serious adverse events. An immune response was observed after primary immunization with Ad26.ZEBOV; boosting by MVA-BN-Filo resulted in sustained elevation of specific immunity. These vaccines are being further assessed in phase 2 and 3 studies.
Auteurs
Langues
- Anglais
Année de publication
2016
Journal
JAMA
Volume
15
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Ebola
Mots-clés
- New vaccine introduction